{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:21:02Z","timestamp":1792480862895,"version":"4.5.0"},"reference-count":23,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Patients with epithelial ovarian cancer (EOC) receiving neoadjuvant platinum-based chemotherapy (NACT) who remain ineligible for complete interval cytoreductive surgery (ICS) due to poor chemosensitivity (CA-125 KELIM\u2122 score &lt;1.0) have a poor prognosis (~20% 5-year survival). A weekly dose-dense carboplatin\u2013paclitaxel regimen may improve outcomes in this high-risk subgroup.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To demonstrate the superiority of a salvage weekly dose-dense carboplatin\u2013paclitaxel regimen over continuation of the standard 3-weekly regimen in poor-prognosis EOC patients after 3\u20134 cycles of standard NACT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>SALVOVAR is a pragmatic, open-label, multicenter, international, randomized phase III trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis:<\/jats:title>\n                    <jats:p>\n                      Patients with stages III\u2013IV high-grade EOC are eligible if they present (1) an unfavorable standardized KELIM score &lt;1.0, and (2) a disease not amenable to complete ICS after 3\u20134 cycles of standard 3-weekly carboplatin\u2013paclitaxel. Patients are randomized (1:1) to either the experimental arm (dose-dense carboplatin AUC5 day 1 plus paclitaxel 80\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      on days 1, 8, and 15, every 3\u2009weeks) or the control arm (continuation of the standard regimen) for 3 cycles. Bevacizumab use is allowed at investigator discretion. Stratification factors include planned bevacizumab administration, BRCA mutation status, and KELIM strata. The two co-primary endpoints are (1) improvement in late complete cytoreduction rates (from 5% in the control arm to 20% in the experimental arm), and (2) overall survival (target hazard-ratio, 0.61). Total 250 patients will be randomized. Secondary endpoints include objective response rate, progression-free survival, and safety. Additional planned analyses include quality-of-life, cost-effectiveness, surgical standardization, human sciences, and biology studies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics:<\/jats:title>\n                    <jats:p>The protocol was approved by the national ethics committee and health authorities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>SALVOVAR will evaluate whether chemotherapy densification improves outcomes in poorly chemosensitive advanced EOC. If positive, this pragmatic strategy could be implemented in large-scale studies, independent of resource setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov NCT06476184 (June-2024). Available at:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT06476184\">https:\/\/clinicaltrials.gov\/study\/NCT06476184<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359251396777","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T07:14:09Z","timestamp":1766560449000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["SALVOVAR: a pragmatic randomized phase III trial comparing the SALVage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic OVARian cancers"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3177-8857","authenticated-orcid":false,"given":"Claire","family":"Chator","sequence":"first","affiliation":[{"name":"Medical Oncology, Lyon University Hospital, EPSILYON, Centre Hospitalier Lyon-Sud, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomu","family":"Yanaihara","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Minato City, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Chabaud","sequence":"additional","affiliation":[{"name":"Biostatistics Unit, Clinical Research and Innovation Department, L\u00e9on B\u00e9rard Cancer Centre, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella Maria","family":"Parma","sequence":"additional","affiliation":[{"name":"European Institute of Oncology IRCCS, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra L.","family":"Dima","sequence":"additional","affiliation":[{"name":"Avedis Donabedian Research Institute, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"},{"name":"Avaluaci\u00f3 de Tecnologies Sanit\u00e0ries en Atenci\u00f3 Prim\u00e0ria i Salut Mental, Institut de Recerca Sant Joan de D\u00e9u, Santa Rosa, Esplugues de Llobregat, Spain"},{"name":"Epidemiology and Public Health, Consortium \u201cCentro de Investigaci\u00f3n Biom\u00e9dica en Red,\u201d Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Clamp","sequence":"additional","affiliation":[{"name":"The Christie Hospital, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwena\u00ebl","family":"Ferron","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Chirurgie, Oncopole Claudius Regaud, IUCT-Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith R.","family":"Kroep","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Leary","sequence":"additional","affiliation":[{"name":"Institut Gustave-Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cibula","sequence":"additional","affiliation":[{"name":"Department of Gynaecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University, General University Hospital in Prague, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Fiteni","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, University Hospital of N\u00eemes, N\u00eemes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Bruchim","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Department, Hillel Yaffe Medical Center, Affiliated with the Ruth and Bruce Rappaport Faculty of Medicine, Technion\u2014Israel Institute of Technology, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Serrier","sequence":"additional","affiliation":[{"name":"Department of Public Health, Health Economic Evaluation Service, Lyon University Hospital, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susannah","family":"Carroll","sequence":"additional","affiliation":[{"name":"Independent Communication Consultant, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Belmont","sequence":"additional","affiliation":[{"name":"Lyon University Hospital, Platefome IC-HCL, Centre Hospitalier Lyon-Sud, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Peron","sequence":"additional","affiliation":[{"name":"Medical Oncology, Lyon University Hospital, EPSILYON, Centre Hospitalier Lyon-Sud, Lyon, France"},{"name":"GINECO, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"You","sequence":"additional","affiliation":[{"name":"Lyon University Hospital, IC-HCL, CICLY, EPSILYON, CITOHL, Lyon University, Lyon 69495, France"},{"name":"GINECO, Paris, France"},{"name":"Service d\u2019Oncologie M\u00e9dicale, Chemin du Grand Revoyet, Pierre-B\u00e9nite, France"},{"name":"Medical Oncology, EPSILYON, Centre Hospitalier Lyon-Sud, Lyon University Hospital, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.21037\/cco-20-34"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21456"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2016.0084"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.07.011"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102294"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0054"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz062"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.05.022"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02589"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.4252"},{"key":"e_1_3_4_12_2","article-title":"#1072 Assessment of the prognostic impact of the European society of gynecologic oncology quality indicators for advanced ovarian cancer surgery","volume":"34","author":"Concin N","year":"2024","unstructured":"Concin N, Grimm C, Villacampa Javierre G, et al. #1072 Assessment of the prognostic impact of the European society of gynecologic oncology quality indicators for advanced ovarian cancer surgery. Int J Gynecol Cancer 2024; 34: A575\u2013A576.","journal-title":"Int J Gynecol Cancer"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01924"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.112966"},{"key":"e_1_3_4_15_2","article-title":"Benefit from fractionated dose-dense chemotherapy in patients with poor prognostic ovarian cancer: ICON-8 trial","volume":"7","author":"Colomban O","year":"2023","unstructured":"Colomban O, Clamp A, Cook A, et al. Benefit from fractionated dose-dense chemotherapy in patients with poor prognostic ovarian cancer: ICON-8 trial. JCO Clin Cancer Inform 2023; 7: e2200188.","journal-title":"JCO Clin Cancer Inform"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.004"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70490-5"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.purol.2020.07.038"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.09.081"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00283-2"},{"key":"e_1_3_4_21_2","article-title":"#159 ICON8B: GCIG phase III randomised trial comparing weekly dose-dense chemotherapy\u2009+\u2009bevacizumab to three-weekly chemotherapy\u2009+\u2009bevacizumab in first-line high-risk stage III-IV epithelial ovarian cancer treatment: primary progression-free survival analysis","volume":"33","author":"Clamp A","year":"2023","unstructured":"Clamp A, Mcneish I, Lord R, et al. #159 ICON8B: GCIG phase III randomised trial comparing weekly dose-dense chemotherapy\u2009+\u2009bevacizumab to three-weekly chemotherapy\u2009+\u2009bevacizumab in first-line high-risk stage III-IV epithelial ovarian cancer treatment: primary progression-free survival analysis. Int J Gynecol Cancer 2023; 33(Suppl. 3): A424.","journal-title":"Int J Gynecol Cancer"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-081477"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02199-2"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106162"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251396777","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359251396777","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251396777","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:33:49Z","timestamp":1777588429000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359251396777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":23,"alternative-id":["10.1177\/17588359251396777"],"URL":"https:\/\/doi.org\/10.1177\/17588359251396777","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"article-number":"17588359251396777"}}